MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another Tablet

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2015-12-14
Last Posted Date
2017-05-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
36
Registration Number
NCT02629354
Locations
🇿🇦

Boehringer Ingelheim Investigational Site, Bloemfontein, South Africa

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

Phase 2
Completed
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
First Posted Date
2015-12-08
Last Posted Date
2019-06-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
21
Registration Number
NCT02624492
Locations
🇪🇸

Hospital La Paz, Madrid, Spain

🇪🇸

Hospital Germans Trias i Pujol, Badalona, Spain

🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

and more 4 locations

All-Case Surveillance of Ofev in Patients With IPF in Japan

Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
First Posted Date
2015-11-18
Last Posted Date
2024-10-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
10117
Registration Number
NCT02607722

Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 695501 prefilled syringe
Drug: BI 695501 autoinjector
First Posted Date
2015-11-17
Last Posted Date
2018-12-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
71
Registration Number
NCT02606903
Locations
🇧🇪

SGS Belgium NV Research Unit Stuivenberg, Antwerpen, Belgium

A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination

Phase 4
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
First Posted Date
2015-11-17
Last Posted Date
2019-03-04
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
37
Registration Number
NCT02606877
Locations
🇬🇧

Papworth Hospital, Cambridge, United Kingdom

🇬🇧

Glenfield Hospital, Leicester, United Kingdom

🇬🇧

Southmead Hospital, Bristol, United Kingdom

and more 6 locations

Patient Convenience Study

Completed
Conditions
Atrial Fibrillation
First Posted Date
2015-11-05
Last Posted Date
2019-02-21
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1852
Registration Number
NCT02597920
Locations
🇧🇪

1160.247.1019 Boehringer Ingelheim Investigational Site, Braine-l'Alleud, Belgium

🇧🇪

1160.247.1018 Boehringer Ingelheim Investigational Site, Brussel, Belgium

🇧🇪

1160.247.1020 Boehringer Ingelheim Investigational Site, Brussels, Belgium

and more 145 locations

Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: 14C-BI 409306
First Posted Date
2015-11-05
Last Posted Date
2024-03-07
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6
Registration Number
NCT02597998
Locations
🇬🇧

Quotient Sciences, Nottingham, United Kingdom

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

Phase 3
Completed
Conditions
Scleroderma, Systemic
Interventions
Drug: Placebo
Drug: Nintedanib
First Posted Date
2015-11-05
Last Posted Date
2019-12-13
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
580
Registration Number
NCT02597933
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇦🇺

St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia

🇧🇪

ULB Hopital Erasme, Bruxelles, Belgium

and more 191 locations

Afatinib in NSCLC With HER2 Mutation

Phase 2
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2015-11-05
Last Posted Date
2019-10-01
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT02597946
Locations
🇨🇳

First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

🇨🇳

Zhejiang Cancer Hospital, Hangzhou, China

🇨🇳

The Second Affiliated Hospital to Nanchang University, Nanchang, China

and more 6 locations

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Completed
Conditions
Venous Thromboembolism
First Posted Date
2015-11-04
Last Posted Date
2020-04-29
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
7797
Registration Number
NCT02596230
Locations
🇬🇷

University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece

🇭🇺

Dr. Kenessey Albert Kórház-Rendelõintézet, Balassagyarmat, Balassagyarmat, Hungary

🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

and more 219 locations
© Copyright 2025. All Rights Reserved by MedPath